Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT00024284
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
1 Year - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.

Key Dates

Start date
Jun 30, 2001
Status verified
Apr 2013
Primary completion
Dec 31, 2003
Completion
Dec 31, 2003

Study Design

Primary purpose
TREATMENT

Locations (6)

FacilityCityStateZIPSite coordinators
Arizona Cancer CenterTucsonArizona85724-
Children's National Medical CenterWashington D.C.District of Columbia20010-2916-
Washington University Medical CenterSt LouisMissouri63105-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-
Children's Hospital of PittsburghPittsburghPennsylvania15213-
St. Jude Children's Research HospitalMemphisTennessee38105-2794-

Find similar trials in Tucson, AZ

By research site
Arizona Cancer Center· Tucson, AZChildren's National Medical Center· Washington D.C., DCWashington University Medical Center· St Louis, MOMemorial Sloan-Kettering Cancer Center· New York, NYChildren's Hospital of Pittsburgh· Pittsburgh, PASt. Jude Children's Research Hospital· Memphis, TN

Related Studies